Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack
Yuan Fang(Ministry of Education of the People's Republic of China), Ying–Hong Shi(Ministry of Education of the People's Republic of China), Wei Xu(Fudan University), Zhen‐Bin Ding(Fudan University), Jun Gao(Fudan University), Yuan‐Fei Peng(Fudan University), Pei‐Yun Zhou(Fudan University), Wei‐Feng Qu(Ministry of Education of the People's Republic of China), Chenyang Tao(Ministry of Education of the People's Republic of China), Han Wang(Hebei Agricultural University), Jin Lei(Fudan University), Jia Fan(Nanjing Tech University), Jian Zhou(Ministry of Education of the People's Republic of China), Zheng Tang(Ministry of Education of the People's Republic of China), Weiren Liu(Fudan University), Xiaoling Wu(Shanghai Medical College of Fudan University), Run Huang(Ministry of Education of the People's Republic of China), Haixiang Sun(Harbin Institute of Technology), Shushu Song(Fudan University), Meng‐Xin Tian(Sun Yat-sen University), Xi‐Fei Jiang(Sun Yat-sen University), Shimin Zhao(Yunnan Institute of Environmental Sciences), Yufu Zhou(Central South University), Xiang Ji(Fudan University)
Cited by 158
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
|Liver Cancer|2020|828